{
    "id": 25401,
    "fullName": "AKT1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "AKT1 positive indicates the presence of the AKT1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 207,
        "geneSymbol": "AKT1",
        "terms": [
            "AKT1",
            "AKT",
            "CWS6",
            "PKB",
            "PKB-ALPHA",
            "PRKBA",
            "RAC",
            "RAC-ALPHA"
        ]
    },
    "variant": "positive",
    "createDate": "09/16/2016",
    "updateDate": "08/22/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4720,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Perifosine (KRX-0401) inhibited Akt1 signaling, inhibited proliferation, and induced apoptosis in human ovarian clear cell cancer cells with activated Akt1 in culture and inhibited tumor growth in cell line xenografts (PMID: 25519148).",
            "molecularProfile": {
                "id": 26309,
                "profileName": "AKT1 positive"
            },
            "therapy": {
                "id": 855,
                "therapyName": "Perifosine",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4674,
                    "pubMedId": 25519148,
                    "title": "Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25519148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4721,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Perifosine (KRX-0401) enhanced the sensitivity of human ovarian clear cell cancer cells with activated Akt1 to Platinol (cisplatin) treatment in culture (PMID: 25519148).",
            "molecularProfile": {
                "id": 26309,
                "profileName": "AKT1 positive"
            },
            "therapy": {
                "id": 3600,
                "therapyName": "Cisplatin + Perifosine",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4674,
                    "pubMedId": 25519148,
                    "title": "Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25519148"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9035,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroendocrine prostate cancer cell line, positive for AKT1, AURKA, and MYCN, demonstrated decreased MYCN expression and reduced cell viability in culture, and decreased tumor volume in xenograft models when treated with CD532 (PMID: 27050099).",
            "molecularProfile": {
                "id": 26699,
                "profileName": "AKT1 pos AURKA pos MYCN pos"
            },
            "therapy": {
                "id": 1628,
                "therapyName": "CD532",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6885,
                    "pubMedId": 27050099,
                    "title": "N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27050099"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9036,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Alisertib (MLN8237) in culture did not result in decreased expression of MYCN and led to minimal effects on cell viability in a neuroendocrine prostate cancer cell line positive for AKT1, AURKA, and MYCN (PMID: 27050099).",
            "molecularProfile": {
                "id": 26699,
                "profileName": "AKT1 pos AURKA pos MYCN pos"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6885,
                    "pubMedId": 27050099,
                    "title": "N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27050099"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11549,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-2206 and KRIBB11 synergistically inhibited Akt1 and Hsf1 activation, resulting in growth inhibition and apoptosis of triple-receptor negative breast cancer cells in culture and in cell line xenograft models (PMID: 28598816).",
            "molecularProfile": {
                "id": 28137,
                "profileName": "AKT1 pos HSF1 pos"
            },
            "therapy": {
                "id": 6057,
                "therapyName": "KRIBB11 + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9624,
                    "pubMedId": 28598816,
                    "title": "Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28598816"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing AKT1 were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32305,
                "profileName": "AKT1 pos NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17049,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing AKT1 demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32305,
                "profileName": "AKT1 pos NRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17250,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of two NRAS-mutant melanoma cell lines with AKT1 expression demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32305,
                "profileName": "AKT1 pos NRAS mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20757,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 treatment inhibited phosphorylation of Akt and S6, reduced viability and induced apoptosis in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 3073,
                "therapyName": "GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 in combination with Platinol (cisplatin) resulted in enhanced reduction in cell viability and induced apoptosis in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 9442,
                "therapyName": "Cisplatin + GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20759,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 in combination with Adrucil (fluorouracil) resulted in enhanced reduction in cell viability and induced apoptosis in in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 9441,
                "therapyName": "Fluorouracil + GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26309,
            "profileName": "AKT1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26699,
            "profileName": "AKT1 pos AURKA pos MYCN pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28137,
            "profileName": "AKT1 pos HSF1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32305,
            "profileName": "AKT1 pos NRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34512,
            "profileName": "AKT1 pos AKT2 pos BCL2 pos FLT3 exon 14 ins",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35327,
            "profileName": "AKT1 pos ARID1A dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}